CSL Limited (ASX:CSL) to build an A$800 million vaccine manufacturing facility

  • November 16, 2020 01:16 PM AEDT
  • Hina Chowdhary
    Hina Chowdhary
    Director, Equities Research Hina Chowdhary
    1706 Posts

    Hina Chowdhary is the Director, Equity Research at Kalkine and has an extensive experience of about 15 years in the area of Research, which includes 5+ years in Equities Research particularly.She has earned a Master of Science degree from the renowne...

CSL Limited (ASX:CSL) to build an A$800 million vaccine manufacturing facility

Summary

  • ASX 200-listed biotech giant CSL Limited is set to build a new influenza vaccine manufacturing facility in Melbourne.
  • The Company intends to invest over A$800 million to optimise cell-based technology.
  • Construction of the plant is anticipated to start in 2021, and the facility is likely to be operational by mid-2026.

ASX 200-listed CSL Limited (ASX:CSL) made headlines this morning after the biotech behemoth announced to build a new vaccine manufacturing facility in Melbourne.

Following the announcement, the share price of CSL was noted at A$315.040, up by 1.803% at AEDT 01:10 PM. The Company has a market capitalisation of almost A$140.79 billion.

Let us discuss CSL’s plan to invest in the construction of a new vaccine manufacturing facility­-

CSL’s Next-generation influenza vaccine manufacturing facility

On 16 November 2020, CSL Limited announced that its wholly-owned subsidiary, Seqirus, plans to invest over A$800 million in the construction of a new biotech manufacturing facility to supply influenza vaccines across Australia and worldwide.

The facility will also manufacture the vaccine division’s proprietary adjuvant MF59®. The substance is added to specific vaccines for improvement in the immune response and to decrease the antigen amount required for each vaccine. This will enable more doses of vaccine to be manufactured at a rapid pace.

The new facility will use innovative cell-based technology for manufacturing of influenza vaccine for seasonal as well as pandemic purposes. The Company is confident that these products can support global markets and will serve the requirements of the Australians.  

CSL stated that the new vaccine facility would be a valuable addition to the global influenza manufacturing supply chain of the Company. Moreover, cell-influenza vaccine technology offers several benefits over the existing process, including being more scalable and offering faster production that is particularly important for influenza pandemics.

The Company disclosed that construction of the state-of-the-art plant is anticipated to start in 2021. The facility is likely to be fully operational by mid-2026.

CSL’s agreement with the Australian government

CSL also notified that this investment decision follows the agreement with the government of Australia to supply vaccines for more than ten years of influenza pandemic protection for the Australian population.

The facility is expected to manufacture influenza pandemic vaccines such as Q-fever vaccines and anti-venoms for Australian animals, including marine creatures, snakes, and spiders.

The Victorian Government will also add to the project to bolster the globally substantial medical research and biotechnology community of Victoria.

Management Commentary

Paul Perreault CSL’s CEO and Managing Director commented-

CSL Limited has been actively involved in COVID-19 vaccine manufacturing and had earlier signed two separate agreements with the Australian government and UK-based biopharmaceutical player AstraZeneca (LON:AZN). The total quantity, as part of the two deals, amounts to 81 million doses.

TO KNOW MORE, READ: CSL Limited (ASX:CSL) Initiates Manufacturing of Oxford/AstraZeneca’s Vaccine Candidate

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK